Company Overview - Solid Biosciences has successfully dosed 33 patients with no reported drug-induced liver injury, myocarditis, or aHUS, indicating a strong safety profile for their treatments [2] - The company has enrolled its first patient in a double-blind, placebo-controlled study, marking a significant milestone in their clinical development [3] Business Development - Solid Biosciences has established 50 different agreements for their capsids, showcasing their growing reputation as a platform technology company [3] - The company is increasingly recognized for its delivery vehicles, which are being utilized in next-generation therapies, reflecting a positive trend in collaboration and innovation [3]